Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adverum Biotechnologies Inc 100 CARDINAL WAY Redwood City CA 94063 USA

www.adverum.com Employees: 121 P: 650-656-9323 F: 650-649-1995

Description:

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.

Key Statistics

Overview:

Market Capitalization, $K 128,348
Enterprise Value, $K 53,348
Shares Outstanding, K 20,802
Annual Sales, $ 3,600 K
Annual Net Income, $ -117,170 K
Last Quarter Sales, $ 1,000 K
Last Quarter Net Income, $ -27,130 K
EBIT, $ -103,100 K
EBITDA, $ -99,390 K
60-Month Beta 1.02
% of Insider Shareholders 4.20%
% of Institutional Shareholders 48.17%
Float, K 19,928
% Float 95.80%
Short Volume Ratio 0.56

Growth:

1-Year Return -33.14%
3-Year Return -68.20%
5-Year Return -94.34%
5-Year Revenue Growth 123.60%
5-Year Earnings Growth 1.69%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.30 on 11/04/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -5.99
EPS Growth vs. Prev Qtr -46.07%
EPS Growth vs. Prev Year 60.61%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 03/21/24

ADVM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -65.14%
Return-on-Assets % -40.52%
Profit Margin % -3,254.72%
Debt/Equity 0.00
Price/Sales 36.11
Price/Cash Flow N/A
Price/Book 0.90
Book Value/Share 6.93
Interest Coverage -1.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar